
More news from the Emerald Isle as the Boston Scientific Corp. (NYSE:BSX) plans to spend $37 million on overseas research and development, this time at its R&D facility in Clonmel, Ireland.
The Natick, Mass.-based company hopes to jump-start development of a next generation cardiac rhythm management system.